Europe’s Last Chance to Revive Its Pharmaceutical Innovation Power

Why It Matters

If Europe fails to reverse its R&D decline, it risks ceding global pharma leadership to the U.S. and China, weakening its economic and strategic influence. Targeted reforms could restore competitiveness and secure a sustainable supply chain for critical medicines.

Key Takeaways

• Europe’s R&D share fell from 50% to 33% since 1990.
• China’s NAS approvals rose 470% versus EU’s 20% decline.
• US holds two‑thirds of pharma profits, driving R&D spending.
• Fragmented EU regulations hinder translational efficiency and market speed.
• Policy reforms needed: price hikes, regulatory harmonization, deeper capital markets.

Pulse Analysis

The erosion of Europe’s pharmaceutical R&D dominance is not merely a statistical footnote; it reflects a structural shift in where high‑value drug discovery occurs. Since the early 1990s, Europe’s contribution to global private R&D has contracted sharply, while the United States has more than doubled its share. Simultaneously, U.S. policy moves—most notably the proposed 25% tariff on imported medicines—have forced a reassessment of pricing, manufacturing locations, and the financing of innovation across the Atlantic. European price controls, intended to keep healthcare affordable, now act as a disincentive for large‑scale investment, further widening the gap.

China’s ascent reshapes the competitive landscape. Over the last decade, the country’s new‑active‑substance approvals exploded by 470%, dwarfing the EU’s 20% decline, and its out‑licensing activity with Western firms has surged to over $50 billion in value. Faster regulatory timelines and a burgeoning pipeline of innovative molecules position China as a credible rival to both the U.S. and Europe. For multinational boardrooms, the strategic calculus now includes a decisive China strategy—whether to pursue aggressive investment and partnership or to adopt a defensive posture to protect existing market share.

Policymakers in Europe have a narrow window to reverse the trend. Raising drug prices in high‑value therapeutic areas, easing claw‑back taxes, and offering targeted tax incentives could de‑risk manufacturing investments. Harmonising clinical‑trial and health‑technology‑assessment processes would cut time‑to‑market, aligning Europe more closely with FDA standards. Finally, deepening capital markets through the Banking, Capital Markets, and Savings Union would unlock early‑stage funding essential for breakthrough research. Implementing these reforms could transform Europe from a laggard into a revitalised hub of pharmaceutical innovation.